Alexis Desieno Sells 24,778 Shares of Cardlytics, Inc. (NASDAQ:CDLX) Stock

Cardlytics, Inc. (NASDAQ:CDLX) CFO Alexis Desieno sold 24,778 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $3.40, for a total transaction of $84,245.20. Following the completion of the transaction, the chief financial officer now owns 140,948 shares of the company’s stock, valued at approximately $479,223.20. The trade was a 14.95 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Alexis Desieno also recently made the following trade(s):

• On Friday, January 3rd, Alexis Desieno sold 8,854 shares of Cardlytics stock. The stock was sold at an average price of $3.67, for a total transaction of $32,494.18.

Cardlytics Trading Down 5.3 %

NASDAQ:CDLX opened at $3.37 on Wednesday. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40. Cardlytics, Inc. has a 12 month low of $2.76 and a 12 month high of $20.52. The company has a market cap of $171.26 million, a PE ratio of -0.55 and a beta of 1.54. The company has a 50 day simple moving average of $3.47 and a two-hundred day simple moving average of $3.73.

Institutional Investors Weigh In On Cardlytics

A number of large investors have recently added to or reduced their stakes in CDLX. GSA Capital Partners LLP grew its position in shares of Cardlytics by 1,273.2% during the 3rd quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock valued at $1,223,000 after acquiring an additional 354,474 shares during the period. RBF Capital LLC grew its position in shares of Cardlytics by 311.9% during the 3rd quarter. RBF Capital LLC now owns 488,128 shares of the company’s stock valued at $1,562,000 after acquiring an additional 369,620 shares during the period. Geode Capital Management LLC grew its position in shares of Cardlytics by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company’s stock valued at $3,371,000 after acquiring an additional 73,484 shares during the period. Barclays PLC grew its position in shares of Cardlytics by 223.9% during the 3rd quarter. Barclays PLC now owns 58,026 shares of the company’s stock valued at $186,000 after acquiring an additional 40,112 shares during the period. Finally, SG Americas Securities LLC grew its position in shares of Cardlytics by 38.2% during the 4th quarter. SG Americas Securities LLC now owns 19,490 shares of the company’s stock valued at $72,000 after acquiring an additional 5,392 shares during the period. Institutional investors own 68.10% of the company’s stock.

Analyst Upgrades and Downgrades

CDLX has been the subject of a number of recent analyst reports. Craig Hallum upgraded shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of Cardlytics in a research report on Friday, January 17th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Cardlytics presently has an average rating of “Hold” and a consensus target price of $6.92.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.